|
KMID : 0191120020170030348
|
|
Journal of Korean Medical Science
2002 Volume.17 No. 3 p.348 ~ p.352
|
|
|
Epirubicin, Cisplatin, and Protracted Venous Infusion of 5-Fluorouracil for Advanced Gastric Carcinoma
|
|
Dong Bok Shin/Eun Kyung Cho
Woon Ki Lee/Do Yoon Lim/Soo Mee Bang/Dong Kyun Park/Yeon Ho Park/Oh Sang Kwon/Duck Joo Choi/Dong Bok Shin/Jae Hoon Lee/Tae Hoon Lee
|
|
|
Abstract
|
|
|
|
To evaluate the activity and safety of a combination chemotherapy with epirubicin, cisplatin, and a protracted venous infusion of 5-fluorouracil (ECF) in unresectable or metastatic gastric cancer, a phase II study was performed. Thirty-five chemotherapy-naive patients were given ECF. Epirubicin (50 mg/m intravenous, IV) and cisplatin (60 mg/m IV) were administered every three weeks during a continuous intravenous infusion of 5-fluorouracil (250 mg/m /day) using infusion pump. One complete response and 19 partial responses (response rate=62%) were achieved. Eight patients remained stable, whereas in four patients the disease progressed. The median duration of response was 22 weeks (95% confidence interval, 18-27 weeks). The median survival for all patients was 10 months (95% confidence interval, 6-14 months), with a 1-yr survival rate of 40%. A total of 184 cycles of chemotherapy were administered. Grade 3 or 4 emesis occurred in 3%, mucositis in 2%, anemia in 10%, and leukopenia in 3% of the cycles. Central venous catheter complications that required line removal occurred in 37% (n=13) of the patients. No patient died of toxicity. Overall, the ECF regimen showed high anti-tumor activity with a tolerable toxicity pattern.
|
|
|
KEYWORD
|
|
|
Gastrointestinal Neoplasms, Epirubicin, Cisplatin, Fluorouracil, Infusion Pumps,
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
    
|
|